2 HIV drugs from Gilead's Stribild fail to win FDA approval as standalones

04/30/2013 | MedCityNews.com

The FDA turned down Gilead Sciences' regulatory applications for elvitegravir and cobicistat as standalone treatments for HIV, citing problems in certain quality testing procedures. The two drugs are included in Gilead's 4-in-1 HIV pill Stribild, which was approved by the FDA last year. Gilead says it is working with the agency to address the issues mentioned in the rejection letter.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY